Drug Treatment of Hypertension in Older Hypertensives

Clinics in Geriatric Medicine

Volumn 25, Issue 2, 2009, Pages 235-244

  Rashidi, Arash ^a   Wright Jr , Jackson T ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b William T Dahms Clinical Research Unit   (United States)

Author keywords

Antihypertensives; Elderly; Geriatrics; Hypertension; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; ISRADIPINE; LISINOPRIL; NIFEDIPINE; PLACEBO; PRAZOSIN; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

AGED; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; REVIEW; STROKE;

AGED; AGED, 80 AND OVER; AGING; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 67449135756     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2009.03.001     Document Type: Review

References (52)

1. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213 7 (1970) 1143-1152
2. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 242 23 (1979) 2562-2571
3. Amery A., Birkenhager W., Brixko P., et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 325 8442 (1985) 1349-1354
4. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265 24 (1991) 3255-3264
5. Liu L., Wang J.G., Gong L., et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 16 12 Pt 1 (1998) 1823-1829
6. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 9080 (1997) 757-764
7. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 19 (2003) 2560-2572
8. Fraker Jr. T.D., Fihn S.D., Gibbons R.J., et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 116 23 (2007) 2762-2772
9. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 9349 (2002) 1903-1913
10. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 9395 (2003) 1527-1535
11. Staessen J.A., Wang J.G., and Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358 9290 (2001) 1305-1315
12. Hansson L. The J-shaped curve. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension: pathophysiology, diagnosis, and management (1995), Raven Press, New York 2765-2770
13. Somes G.W., Pahor M., Shorr R.I., et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 159 17 (1999) 2004-2009
14. Messerli F.H., Mancia G., Conti C.R., et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 12 (2006) 884-893
15. Fagard R.H., Staessen J.A., Thijs L., et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 167 17 (2007) 1884-1891
16. Buse J.B., Bigger J.T., Byington R.P., et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99 12A (2007) 21i-33i
17. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 24 (2008) 2545-2559
18. Buhler F.R. Antihypertensive treatment according to age, plasma renin and race. Drugs 35 (1988) 495-503
19. Williams G.H. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 319 23 (1988) 1517-1525
20. Materson B.J., Reda D.J., Cushman W.C., et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328 13 (1993) 914-921
21. Johnson E.F., and Wright Jr. J.T. Management of hypertension in Black populations. In: Oparil S., and Weber M. (Eds). Hypertension. A companion to Brenner and Rector's: the kidney (2005), Elsevier, Philadelphia 587-602
22. Gasowski J., Birkenhager W.H., Staessen J.A., et al. Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial. Cardiovasc Drugs Ther 14 1 (2000) 49-53
23. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 9192 (1999) 1751-1756
24. Brown M.J., Palmer C.R., Castaigne A., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356 9227 (2000) 366-372
25. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 15 (2008) 1547-1559
26. Oparil S., Yarows S.A., Patel S., et al. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 370 9593 (2007) 1126-1127
27. Wright Jr. J.T., Probstfield J., Cushman W.C., et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 169 9 (2009) 1-11
28. Messerli F.H., Grossman E., and Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279 23 (1998) 1903-1907
29. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 9496 (2005) 1545-1553
30. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update (2006), Royal College of Physicians, London
31. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 23 (2002) 2981-2997
32. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42 3 (2003) 239-246
33. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 8 (2005) 936-946
34. Wright Jr. J.T., Harris-Haywood S., Pressel S., et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome in ALLHAT. Arch Intern Med 168 (2008) 1-11
35. Psaty B.M., Smith N.L., Siscovick D.S., et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277 9 (1997) 739-745
36. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 23 (2008) 2417-2428
37. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 9287 (2001) 1033-1041
38. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 9426 (2004) 2022-2031
39. Weber M.A., Julius S., Kjeldsen S.E., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363 9426 (2004) 2049-2051
40. Wright Jr. J.T., Dunn J.K., Cutler J.A., et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 293 13 (2005) 1595-1608
41. Jones G., Nguyen T., Sambrook P.N., et al. Thiazide diuretics and fractures: can meta-analysis help?. J Bone Miner Res 10 1 (1995) 106-111
42. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 18 (2008) 1887-1898
43. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153
44. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 9153 (1999) 611-616
45. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 995-1003
46. Hansson L., Hedner T., Lund-Johansen P., et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356 9227 (2000) 359-365
47. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 9489 (2005) 895-906
48. Black H.R., Elliott W.J., Grandits G., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289 16 (2003) 2073-2082
49. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 304 6824 (1992) 405-412
50. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 9386 (2003) 782-788
51. Nissen S.E., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 18 (2004) 2217-2225
52. The ONTARGET Investigator. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. NEJM 358 (2008) 1547-1549